At ELRIG 2024, Dr. Maria Duca described how her lab’s rational design approach bypasses lengthy screening protocols.

Novo Nordisk’s chief scientific officer Marcus Schindler led the keynote address at ELRIG Drug Discovery 2024 in London, UK.

Resolution plans to use Series B investment to advance the development of its macrophage therapies in inflammatory and ...

Vevizye is used to treat moderate to severe DED in adults unresponsive to tear substitutes. Novaliq and Laboratoires Théa ...

Enara Bio has raised $32.5m in a Series B financing round to advance its platform shining a light on cancer-specific antigens ...

GLP-1 RAs are being recommended on social media, raising questions about who can see the content and what the effects might ...

Eli Lilly has announced a $4.5bn investment to establish the Lilly Medicine Foundry for drug production and manufacturing ...

ImmunoPrecise Antibodies, an AI-driven biotherapeutic research and technology company, has entered into a material transfer ...

Gilead Sciences has announced the signing of voluntary licencing agreements with six generic pharmaceutical manufacturers to ...

Sofgen, a supplier of softgel technologies for generics, prescription drugs, OTC products and specialised nutraceuticals, ...

Under the terms of the deal announced yesterday (30 September), Massachusetts-based Prime Medicine will design gene editing ...